Welcome to the Golden age for Gene Editing!
Nuclease-based gene editing technology has opened up how biotechs approach genomic research in industry. A…
The gene-editing tool CRISPR-Cas9 has taken over the life sciences world since its development in 2012. CRISPR has changed the way biology research is done, simplifying and speeding up the study of diseases and the discovery of drugs, as well as having a huge impact on crop and food development. Among all its possible applications, the fact that CRISPR can be used to tweak the human genome has made it especially promising for previously difficult-to-treat diseases.
But how does CRISPR work? What kind of therapies are being developed? How is the genome-editing market evolving? And how are stakeholders navigating the complex intellectual property around this technology? Find out the answers to these questions and more on this page.
The Genome Editing Toolbox: ZFNS, TALENS, and CRISPR in Biomedicine
This report covers the industry’s most common genome-editing tools, like CRISPR-Cas9, provides exclusive insights by experts, looks at the market, and addresses future applications and challenges of genome-editing tools.
Go to ReportNuclease-based gene editing technology has opened up how biotechs approach genomic research in industry. A…
Encouraging facts for the European Biotech ecosystem this week! Neil Woodford's mega Biotech fund is…
French, young and brilliant, Emmanuelle Charpentier will now be working as a director at the Max…
A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership…
The Holidays are a perfect time to enjoy the sun and relax peacefully on the…
Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration…
Antibiotic resistance is a public health problem worldwide. According to WHO, by 2050, over 10 million…
PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on…
CRISPR continues to amass prizes and to consolidate itself as the biggest discovery of the…
Antibiotics abuse is creating a whole new generation of antibiotic-resistant bacteria. As the tolerance to…
As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B…
Desktop Genetics has just launched the DeskGen Platform for gene editing. It combines elements of the…